The FDA’s Audacious Move to Boost Kids Aged 5-11yrs
Some members have raised concerns that the drug regulator has repeatedly moved ahead with decisions on booster doses without holding open public discussions and say the agency is relying less and less on its independent experts for advice before approving drugs.
The FDA’s Audacious Move to Boost Kids Aged 5-11yrs Read Journal Article